Trial Profile
To compare real world treatment outcomes and costs among patients received lenalidomide maintainence therapy in patients with newly diagnosed multiple myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology